Literature DB >> 27439493

Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.

Yumi Koike1,2, Tetsuya Kawabe1,3, Kanami Nishihara1, Naomi Iwane1,4, Takuzo Hano1.   

Abstract

The pupil is a suitable end organ for studying autonomic function because both sympathetic and parasympathetic nerve activity can be evaluated independently using a light stimulus. Sympathetic response elicited by physical stress is augmented in hypertensive patients compared with normotensive subjects, which increases the risk of cardiovascular events. We used pupillometry to evaluate the effects of the calcium channel blockers azelnidipine (AZ) and amlodipine (AM) on changes in autonomic nervous activity induced by isometric exercise in patients with hypertension. Twenty patients with essential hypertension who were administered AM and 21 who were administered AZ underwent a pupillary function test and blood pressure (BP) and pulse rate (PR) measurements before and after isometric handgrip exercise (IHG). Maximal velocities of pupil constriction (VC) and re-dilation (VD) obtained with light stimulation for 1 s were used as indices of parasympathetic and sympathetic nerve activity, respectively. Increases in systolic BP and PR elicited by IHG were significantly smaller in the AZ group than in the AM group. After IHG, both VC and VD significantly increased in the AM group but not in the AZ group. The low-to-high frequency ratio obtained from analysis of PR variability, another measure of sympathetic activity, also increased in only the AM group. Thus AZ inhibited autonomic activation and suppressed cardiovascular responses to IHG more effectively than AM. The sympathoinhibitory effect of AZ may therefore be beneficial for patients with essential hypertension. In addition, pupillometry was shown to be a useful tool for assessing autonomic function in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27439493     DOI: 10.1038/hr.2016.94

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  47 in total

1.  Nomenclature of voltage-gated calcium channels.

Authors:  E A Ertel; K P Campbell; M M Harpold; F Hofmann; Y Mori; E Perez-Reyes; A Schwartz; T P Snutch; T Tanabe; L Birnbaumer; R W Tsien; W A Catterall
Journal:  Neuron       Date:  2000-03       Impact factor: 17.173

2.  Automated standardized pupillometry with optical method for purposes of clinical practice and research.

Authors:  F Fotiou; K N Fountoulakis; A Goulas; L Alexopoulos; A Palikaras
Journal:  Clin Physiol       Date:  2000-09

3.  Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.

Authors:  Kizuku Kuramoto; Shuichi Ichikawa; Aizan Hirai; Shigeto Kanada; Tetsu Nakachi; Toshio Ogihara
Journal:  Hypertens Res       Date:  2003-03       Impact factor: 3.872

4.  Trends in blood pressure control and medication use during 20 years in a hypertension clinic in Japan.

Authors:  Yasuo Kansui; Ai Ibaraki; Kenichi Goto; Yoshie Haga; Takunori Seki; Tomohiro Takiguchi; Toshio Ohtsubo; Takanari Kitazono; Kiyoshi Matsumura
Journal:  Clin Exp Hypertens       Date:  2016-03-30       Impact factor: 1.749

5.  Effects of the cold pressor test on muscle sympathetic nerve activity in humans.

Authors:  R G Victor; W N Leimbach; D R Seals; B G Wallin; A L Mark
Journal:  Hypertension       Date:  1987-05       Impact factor: 10.190

6.  Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients.

Authors:  Kazuo Eguchi; Kazuomi Kario; Kazuyuki Shimada
Journal:  Hypertens Res       Date:  2002-05       Impact factor: 3.872

7.  Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.

Authors:  Teru Nada; Masahiro Nomura; Kunihiko Koshiba; Tomohito Kawano; Jyunichi Mikawa; Susumu Ito
Journal:  Arzneimittelforschung       Date:  2007

Review 8.  Noradrenaline release and the pathophysiology of primary human hypertension.

Authors:  M Esler; G Jennings; G Lambert
Journal:  Am J Hypertens       Date:  1989-03       Impact factor: 2.689

9.  Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.

Authors:  Jun-ichiro Inomata; Hisayoshi Murai; Shuichi Kaneko; Takuto Hamaoka; Tatsunori Ikeda; Daisuke Kobayashi; Soichiro Usui; Hiroshi Furusho; Yu Sugiyama; Shigeo Takata; Masayuki Takamura
Journal:  J Hypertens       Date:  2014-09       Impact factor: 4.844

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  3 in total

Review 1.  Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review.

Authors:  C Venkata S Ram
Journal:  Cardiol Ther       Date:  2022-08-13

2.  The Function of the Autonomic Nervous System in Asian Patients With Chronic Migraine.

Authors:  Min Shi; Danqing Luo; Jun Guo; Dongdong Yang; Zhaoying Li; Huan Zhao
Journal:  Front Neurosci       Date:  2022-04-14       Impact factor: 4.677

3.  Sympathetic modulation by antihypertensive drugs.

Authors:  Kenichi Katsurada; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-08-03       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.